Accession Number:



Integrated Genomic Biomarkers to Identify Aggressive Disease in African Americans with Prostate Cancer

Descriptive Note:

Technical Report,01 Sep 2015,31 Aug 2019

Corporate Author:

Henry Ford Health System Detroit United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Robust methods for risk stratification of prostate tumors are needed to enable men and their physicians to safely select between post-treatment surveillance and immediate adjuvant therapy. The purpose of our research is to use a multi-omic approach to identify somatic copy number alterations and methylation markers in the primary tumors of African American men that can serve as a component of their recurrence risk assessment and be applied in treatment planning to help reduce the racially disparate rates of mortality from CaP. Through whole genome copy number alteration and methylation scans, the study will identify individual and integrated DNA-based biomarkers of biochemical recurrence in 200 African American men 100 with and 100 without biochemical recurrence. These biomarkers will then be validated in an independent set of 200 African American men.

Subject Categories:

  • Medicine and Medical Research
  • Biochemistry
  • Genetic Engineering and Molecular Biology

Distribution Statement: